The Center for Genetics and Society brings social justice and human rights to the center of public and policy discussions about human genetics and assisted reproduction.

Featured

Biopolitical Times

CGS’ Gender Justice and Disability Rights Coalition has just released Social Justice and Human Rights Principles for Global Deliberations on Heritable Genome Editing. The Principles explicitly center gender justice, disability rights, and human rights in deliberations addressing heritable genome editing, an arena that has largely been the purview of scientists and bioethicists. The Principles have been endorsed by more than 70 individuals and organizations from around the world.

Heritable genome editing – using CRISPR or other tools to alter...

CGS-authored

Eugenics is widely regarded as a debunked pseudoscience—developed and promoted mostly in Nazi Germany—that fell off the political radar after the horrors of the Holocaust were revealed. In fact, twentieth century eugenics represented the mainstream science of its day and...

Biopolitical Times

Note: This article was originally published in February 2024 in issue 268 of the German-language journal Der Gen-ethische Informationsdienst (GID)...

Biopolitical Times

The 1932 kidnapping and murder of Charles Lindbergh’s 20-month-old son was called the “crime of the century” at the time...

Biopolitical Times

Note: This article was originally published in February 2024 in issue 268 of the German-language journal Der Gen-ethische Informationsdienst (GID)...

23andMe’s stock price since late 2020

23andMe, the first-off-the-blocks personal genomics company, has been struggling lately. In October, there were...

News

Today, Massachusetts Institute of Technology biologist Kevin Esvelt is well known for his work on guided evolution technologies—creating systems for evolving biomolecules in the lab and developing techniques to shape the evolutionary trajectories of species in the wild—as well as...

A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.

The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...

The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...

When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief. 

Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...

Video

Reproduction and Family Formation: The State and the Market
Use Gene Editing to Make Better Babies | Debate | Intelligence Squared U.S.
The 'Perfect' Baby?: The Dangers of Gene Editing in Assisted Reproduction